Stockreport

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]

Aprea Therapeutics, Inc.  (APRE) 
PDF Aprea Therapeutics Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometri [Read more]